CGEM

Cullinan Therapeutics (CGEM)

About Cullinan Therapeutics (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Details

Daily high

$18.43

Daily low

$17.38

Price at open

$18.14

52 Week High

$19.43

52 Week Low

$5.68

Market cap

1.1B

Dividend yield

0.00%

Volume

361,755

Avg. volume

554,219

P/E ratio

-4.83

Cullinan Therapeutics News